Article Text
Correspondence
Efficacy of methyprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson’s disease
Statistics from Altmetric.com
I was astonished to find that Sato and colleagues were able to identify 40 cases of neuroleptic malignant syndrome (NMS) in patients with Parkinson’s disease from a single institution over three years.1 At a recent neurosciences grand round in Birmingham, UK, which has an interest in Parkinson’s disease research, we could only recall two such cases in living memory.
There are two possible explanations for this high incidence of NMS. Firstly, in Japan the Parkinson’s disease population may be more prone to developing NMS when their anti-parkinsonian medication is reduced. This could be due to genotypic differences between Japanese and Western populations. …